{"id":711207,"date":"2024-08-26T17:26:01","date_gmt":"2024-08-26T17:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=711207"},"modified":"2024-08-26T17:26:01","modified_gmt":"2024-08-26T17:26:01","slug":"hemato-oncology-testing-market-worth-56-billion-by-2027","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hemato-oncology-testing-market-worth-56-billion-by-2027_711207.html","title":{"rendered":"Hemato Oncology Testing Market worth $5.6 billion by 2027"},"content":{"rendered":"
\n
\"Hemato<\/a><\/div>\n
\n
North America dominated hemato oncology testing market. The largest share can be attributed to the significant advances have been made in cancer treatment driven by advances in personalized medicine, increasing co-development projects, and increasing collaborations for developing new assay tests.<\/div>\n<\/div>\n<\/div>\n
Browse 97 market data Tables and 32 Figures spread through 145 Pages and in-depth TOC on “Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User – Global Forecast to 2027<\/div>\n

Hemato Oncology Testing Market<\/a><\/strong> is projected to reach USD 5.6 billion by 2027 from an estimated USD 2.9 Billion in 2022, at a CAGR of 14.2% according to a new report by MarketsandMarkets™.<\/strong> The growth in this market is attributed to the growing incidence of hematologic cancer, increasing collaborations, and the increasing number of conferences on personalized medicine.<\/p>\n

Download PDF Brochure:<\/strong> https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=262472877<\/a><\/strong><\/p>\n

The Services segment accounted for the largest share of the Hemato oncology testing devices market, by product type, in 2021<\/strong><\/p>\n

On the basis of products & services type, the global hemato oncology testing market is segmented into services and assay kits. The services segment accounted for the largest share of the global hemato oncology testing market in 2021. This can be attributed to the high and growing prevalence of leukemia and lymphoma.<\/p>\n

The segment accounted for the largest share of the Hemato oncology testing devices market, by cancer type, in 2021<\/strong><\/p>\n

By cancer type, the global leukemia, lymphoma, and other cancers market. In 2021, the lymphoma segment dominated the global market.  This can be attributed to factor such as the increasing prevalence and incidence of lymphoma is a major driving factor for this market.<\/p>\n

PCR segment is anticipated to hold major share of the global Hemato oncology testing market in 2021<\/strong><\/p>\n

By technology, the global hemato oncology testing market is broadly segmented into PCR, IHC, NGS, cytogenetics, and other technologies. In 2021, the PCR segment dominated hemato oncology testing market. Factors supporting the growth of the segment is  the wide use of this technology owing to its ease of use and easy availability of assay kits.<\/p>\n

Request Sample Pages: <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=262472877<\/a><\/strong><\/p>\n

North America to hold a significant share of the Hemato oncology testing market during the forecast period in 2021<\/strong><\/p>\n

The global hemato oncology testing market is segmented into North America, Europe, Asia Pacific, and ROW. North America dominated hemato oncology testing market. The largest share can be attributed to the significant advances have been made in cancer treatment driven by advances in personalized medicine, increasing co-development projects, and increasing collaborations for developing new assay tests.<\/p>\n

The major players operating in the Hemato oncology testing market Abbott Laboratories (US), F. Hoffman-La Roche (Switzerland), QIAGEN (Germany), Thermo Fisher Scientific (US), Illumina (US), Bio-Rad Laboratories (US), MolecularMD (Ireland), ArcherDX (US), ARUP Laboratories (US), Asuragen (US), Invivoscribe (US), Adaptive Biotechnologies (US), Amoy Diagnostics (China), ELITechGroup (France), Vela Diagnostics (Singapore), Gentronix (UK), BioIVT (US), SAGA Diagnostics (Sweden), Olink (Sweden) and Cancer Diagnostics (US).<\/p>\n

Get 10% Free Customization on this Report:<\/strong> https:\/\/www.marketsandmarkets.com\/requestCustomizationNew.asp?id=262472877<\/a><\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets\u2122 Research Private Ltd.<\/a>
Contact Person:<\/strong> Mr. Aashish Mehra
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>630 Dundee Road Suite 430
City:<\/strong> Northbrook
State:<\/strong> IL 60062
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.prnewswire.com\/news-releases\/hemato-oncology-testing-market-worth-5-6-billion-by-2027—exclusive-report-by-marketsandmarkets-301685926.html<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

North America dominated hemato oncology testing market. The largest share can be attributed to the significant advances have been made in cancer treatment driven by advances in personalized medicine, increasing co-development projects, and increasing collaborations for developing new assay tests. … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-711207","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/711207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=711207"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/711207\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=711207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=711207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=711207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}